Ask AI
ProCE Banner Activity

La prospettiva europea sugli approcci odierni per l’ottimizzazione delle cure dei pazienti affetti da linfoma mantellare

PDF

Nel presente commentario, un esperto parla del ruolo in continua espansione degli inibitori di BTK e dei regimi terapeutici senza chemioterapia nella gestione dei pazienti affetti da linfoma mantellare (Mantle Cell Lyphoma, MCL) e dell’importanza della gestione proattiva degli eventi avversi correlati al trattamento per prolungare il tempo in cui il paziente rimane in trattamento e migliorare gli esiti clinici e la qualità della vita.

Released: February 24, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This activity is intended for global hematology/oncology physician specialists and other healthcare professionals providing care for patients with mantle cell lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan BTK inhibitor-based combination strategies for patients with treatment-naïve MCL, considering new indications, expert recommendations, and available efficacy and safety evidence

  • Select chemotherapy-free treatment strategies for appropriate patients with MCL

  • Manage treatment-related adverse events associated with targeted therapies alone or in combination to extend duration on treatment and improve clinical outcomes